Publicacións nas que colabora con Salvador Martín Algarra (15)

2015

  1. Early prediction of disease progression in small cell lung cancer: Toward model-based personalized medicine in oncology

    Cancer Research, Vol. 75, Núm. 12, pp. 2416-2425

2014

  1. A population pharmacodynamic model for lactate dehydrogenase and neuron specific enolase to predict tumor progression in small cell lung cancer patients

    AAPS Journal, Vol. 16, Núm. 3, pp. 609-619

2011

  1. Assessment of epidermal growth factor receptor and krasmutation status in cytological stained smears of non-small celllung cancer patients: Correlation with clinical outcomes

    Oncologist, Vol. 16, Núm. 6, pp. 877-885

2005

  1. Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung center: Two case reports and a review of the literature

    Clinical Lung Cancer, Vol. 7, Núm. 2, pp. 138-140

  2. Disnea, oliguria y edema en extremidades inferiores en paciente en tratamiento de radioterapia mediastínica por carcinoma tímico irresecable

    Clinical and Translational Oncology, Vol. 7, Núm. 2, pp. 74-77

2004

  1. A single prior course of BCNU-cisplatin chemotherapy has a significant deleterious effect on mobilization kinetics of otherwise untreated patients

    Bone Marrow Transplantation, Vol. 33, Núm. 5, pp. 499-502

  2. Paclitaxel, cisplatin, and vinorelbine combination chemotherapy in metastatic non-small-cell lung cancer

    American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 27, Núm. 3, pp. 299-303

  3. Preliminary experience with intensity modulated radiation therapy for abdominopelvic tumor sites: A comparison with 3D radiotherapy plans

    Clinical and Translational Oncology, Vol. 6, Núm. 7, pp. 415-423

  4. Preliminary experience with intensity modulated radiation therapy for abdominopelvic tumor sites: a comparison with 3D radiotherapy plans

    Revista de oncología: Publicación oficial de la Federación de Sociedades Españolas de Oncología y del Instituto Nacional de Cancerología de México, Vol. 6, Núm. 7, pp. 415-423

2003

  1. Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer

    Oncology, Vol. 64, Núm. 1, pp. 28-35

  2. Surgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancer

    American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 26, Núm. 1, pp. 30-36

2002

  1. Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer: A feasibility pilot study

    Oncology, Vol. 63, Núm. 3, pp. 254-265

  2. Radiation therapy after high-dose chemotherapy with peripheral blood stem cell support for high-risk breast cancer

    American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 25, Núm. 4, pp. 347-353

  3. Second-line chemotherapy with irinotecan and vinorelbine in stage IIIb and IV non-small-cell lung cancer: A phase II study

    American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 25, Núm. 5, pp. 480-484

1996

  1. High-dose BCNU and autologous progenitor cell transplantation given with intra-arterial cisplatinum and simultaneous radiotherapy in the treatment of high-grade gliomas: Benefit for selected patients

    Bone Marrow Transplantation, Vol. 18, Núm. 1, pp. 143-149